3 Stocks Pulling The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 73 points (0.4%) at 16,911 as of Tuesday, Aug. 19, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,966 issues advancing vs. 988 declining with 181 unchanged.

The Health Care sector currently sits down 0.2% versus the S&P 500, which is up 0.4%. On the negative front, top decliners within the sector include Hospira ( HSP), down 1.9%, Gilead ( GILD), down 1.0%, Fresenius Medical Care AG & Co. KGaA ( FMS), down 0.9%, HCA Holdings ( HCA), down 0.7% and GlaxoSmithKline ( GSK), down 0.6%. Top gainers within the sector include Grifols ( GRFS), up 2.9%, Valeant Pharmaceuticals International ( VRX), up 1.6%, UnitedHealth Group ( UNH), up 1.5%, Allergan ( AGN), up 0.8% and AbbVie ( ABBV), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Illumina ( ILMN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Illumina is down $1.55 (-0.9%) to $170.73 on light volume. Thus far, 388,591 shares of Illumina exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $170.65-$174.00 after having opened the day at $172.24 as compared to the previous trading day's close of $172.28.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $23.5 billion and is part of the drugs industry. Shares are up 55.8% year-to-date as of the close of trading on Monday. Currently there are 10 analysts that rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, compelling growth in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Illumina Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $2.99 (-0.9%) to $346.47 on light volume. Thus far, 206,172 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 842,000 shares. The stock has ranged in price between $345.09-$351.42 after having opened the day at $349.94 as compared to the previous trading day's close of $349.46.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $34.5 billion and is part of the drugs industry. Shares are up 27.0% year-to-date as of the close of trading on Monday. Currently there are 8 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Amgen ( AMGN) is down $1.15 (-0.9%) to $132.07 on light volume. Thus far, 617,437 shares of Amgen exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $132.06-$133.69 after having opened the day at $133.36 as compared to the previous trading day's close of $133.22.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $100.9 billion and is part of the drugs industry. Shares are up 16.8% year-to-date as of the close of trading on Monday. Currently there are 7 analysts that rate Amgen a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, reasonable valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing